Expression of membrane-bound Interleukin-15 sustains the growth and survival of CAR-NK cells
Authors:
- 23 September 2025
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 166, 115577
Abstract
No abstract availableKeywords
Funding Information
- Major Scientific and Technological Project of Zhejiang Province (2024C03157, 2023C03061, 2023SDYXS0001)
This publication has 44 references indexed in Scilit:
- IL-15 in CAR engineering: striking an efficacy–safety balanceTrends in Molecular Medicine, 2025
- Interleukin-enhanced CAR-engineered immune cells in tumor immunotherapy: current insights and future perspectivesCytokine, 2025
- Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancerMolecular Therapy, 2025
- Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapyTrends in Immunology, 2022
- piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cellsMolecular Therapy - Methods & Clinical Development, 2021
- Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cellsMolecular Therapy - Methods & Clinical Development, 2021
- Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patientsJournal of Cancer Research and Clinical Oncology, 2021
- T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor EradicationMolecular Therapy, 2021
- Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor XenograftsMolecular Therapy-Oncolytics, 2020
- Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based ApproachTransplantation and Cellular Therapy, 2015